Skip to Main Content

Did the critics of Acadia Pharmaceuticals — and I’m very much included in that group — underestimate the efficacy of the drugmaker’s antipsychotic medicine Nuplazid? Or, did we fail to appreciate Acadia’s cleverness in designing a clinical trial for a mediocre medicine that could still deliver a positive result?

Maybe I’m stubborn, but I lean towards the latter. Still, there is no denying that Monday is a very good day for Acadia and those who believe in Nuplazid’s potential to be a more widely used antipsychotic drug. A Phase 3 clinical trial investigating Nuplazid as a treatment for dementia-related psychosis was stopped early for positive efficacy, Acadia announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • hi Adam
    are you generally against enrichment trials (if that’s what it could be called)? i understand your point about sedation – may as well use haloperidol if that is the main effect as there seems to be an issue with prolonging QT of combination products as well. if most (75% plus?) of the patients responded in the run-up part of the trial and entered the blinded phase (though i suppose difficult to be blinded if the placebo isn’t sedating) then that would be ok wouldn’t it? if they lost more than 50% in the run-up, that would suggest a niche product at best. I suppose the data need to be published…..

  • Let’s imagine that early criticism of the clinical trial were to have enough widespread reading so as to collapse the stock price and prevent further development of the drug (resulting inability to raise capital). Let’s also assume that this positive news is real. That means patients would suffer by not having access to a drug that would have otherwise continued development.

Comments are closed.